Science News

NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The co...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today full results from the Phase III FIND-CKD trial investigating KERENDIA® (finerenone) in adults with non-diabetic chronic kidney disease (nd-CKD) who were also receiving background standard of care. In the trial, KERENDIA met the primary endpoint by showing a significant reduction in the rate of kidney disease progression, as measured by estimated glomerular filtration rate (eGFR) slope (mean annual change from baseline to month...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of...

LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced the publication of clinical data from its Phase 2 (RAINBOW) study in the peer reviewed journal, Molecular Genetics & Metabolism. The published manuscript reports efficacy, safety, pharmacokinetic and pharmacodynamic data which evaluated nizubaglustat in patients with genetically confirmed...

HOUSTON--(BUSINESS WIRE)--Goldenrod Therapeutics, innovator in brain inflammation treatments for neurological conditions, completed initial close on $6.5 million Series Seed....

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 8, 2026. Members of the Summit management team will participate in a fireside chat presentation at 10:00 AM ET, providing a corporate overview and update on recent progress, including the development of its innovative investigational bispecific antibody, ivonescimab. The presentatio...

FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) today announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. The acquisition adds gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager, to Gilead’s growing inflammation portfolio and will be the foundation of Lakefront’s clinical de...

LITTLETON, Mass.--(BUSINESS WIRE)--Mevion Medical Systems, a global leader in compact proton therapy, today announced that the world’s first clinical proton therapy treatment delivered inside an existing conventional radiation therapy vault has been completed at Stanford Medicine Cancer Center. The treatment was delivered on the MEVION S250-FIT Proton Therapy System™. The milestone establishes a new category of proton therapy delivery: a compact single-room system that fits within existing radi...

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that VOYXACT® (sibeprenlimab-szsi) preserved kidney function compared to placebo over 12 months in adults with primary IgA nephropathy (IgAN) at risk for disease progression. VOYXACT demonstrated an increase in mean change for the estimated glomerular filtration rate (eGFR) from baseline of +0.7 mL/min/1.73 m2 compared to a declin...

MANHASSET, N.Y.--(BUSINESS WIRE)--Bridging the critical gap from lab bench to patient bedside, the Elmezzi Graduate School of Molecular Medicine at Northwell Health’s Feinstein Institutes for Medical Research celebrated its newest physician-scientist graduates trained to bringing scientific discovery into life-changing therapies. A commencement ceremony was held on May 21 at the Feinstein Institutes where Alexandra Bekiaridou, MD, PhD, and Russell Hollis, MD, PhD, received their PhD degrees, an...